Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis
- PMID: 37563978
- DOI: 10.1111/1756-185X.14845
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis
Comment on
-
Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.Ann Rheum Dis. 2023 Jan;82(1):154-160. doi: 10.1136/ard-2022-222849. Epub 2022 Aug 12. Ann Rheum Dis. 2023. PMID: 35961761 Free PMC article. Clinical Trial.
References
REFERENCES
-
- Weiss PF, Fuhlbrigge RC, von Scheven E, et al. Children with enthesitis-related arthritis and possible benefits from treatments for adults with spondyloarthritis. Arthritis Care Res. 2022;74:10581064.
-
- Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an International Task force. Ann Rheum Dis. 2018;77:819-828.
-
- Stefania N, Giovanni R, Riccardo M, et al. Treatment of psoriatic arthritis with secukinumab: a case series. J Dermatol Treat. 2018;29(Suppl 1):6-8.
-
- Oya K, Ayten A, Sezgin S, et al. An overview of the relationship between juvenile idiopathic arthritis and potential environmental risk factors: do early childhood habits or habitat play a role in the affair? Int J Rheum Dis. 2022;25(12):1376-1385.
-
- Brunner HI, Foeldvari I, Alexeeva E, et al. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial. Ann Rheum Dis. 2023;82(1):154-160.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

